Breaking News, Collaborations & Alliances

BMS, ZymoGenetics Enter Global Hep-C Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and ZymoGenetics, Inc. entered a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program. Under the terms of the collaboration, ZymoGenetics will receive an upfront cash payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, and will receive an additional license fee of $20 million in 2009. ZymoGenetics could ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters